U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07121244) titled 'A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer' on Aug. 06.
Brief Summary: A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.
Study Start Date: Sept. 15
Study Type: INTERVENTIONAL
Condition:
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
Metastatic Hormone Receptor Positive Breast Cancer
Intervention:
DRUG: 68Ga-R11228
68Ga-R11228 is a gallium-labeled small molecule radioligand that is designed to localize tumor lesions
DRUG: 177Lu-R11228
177Lu-R11228 is a lutetium-labeled small molecule radioligand designed to treat tumor lesions
Recruitment Status: NOT_YET_RECRUITING
Sp...